Business
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
neffy is available in pharmacies this week and the lowest discounted cash price at retail pharmacies can be found exclusively at GoodRx neffy is the first
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"\nneffy is available in pharmacies this week and the lowest discounted cash price at retail pharmacies can be found exclusively at GoodRx\n\nneffy is the first and only needle-free treatment for Type I allergic reactions, including anaphylaxis for adults and children who weigh ≥30 kg (66 lbs.)\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. (“ARS Pharmaceuticals”) to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store this week, consumers who have been prescribed neffy can now access a pack of two single-use neffy devices for $199 at more than 70,000 pharmacies nationwide exclusively through GoodRx.\n\nApproved by the Food and Drug Administration in August, neffy is the first needle-free treatment for Type I allergic reactions, including anaphylaxis, offering an innovative alternative to auto-injectors. Unlike traditional methods, neffy delivers epinephrine nasally, avoiding needle injections.\n\n\"At GoodRx, we’re not just motivated by making essential medications more accessible and affordable, but also by championing innovation within well-established markets,\" said Dorothy Gemmell, Chief Commercial Officer at GoodRx. “We’re committed to offering neffy at a lower price so we can help break down long-standing barriers in anaphylaxis treatment and offer an option that millions of people, especially children and adults who need to carry epinephrine, can use to receive timely and effective treatment.”\n\nAllergies and allergy symptoms impact over 100 million Americans annually, with more than 50 million experiencing an allergic reaction each year, underscoring the critical need for accessible treatment. Anaphylaxis, a severe allergic reaction involving the whole body, can induce symptoms such as difficulty breathing, fast heartbeat, hives, nausea, and in severe cases, loss of consciousness, often occurring within seconds or minutes of exposure to an allergen. neffy provides a much-needed option that enhances accessibility and affordability for millions of Americans.\n\n“We’re thrilled about neffy’s U.S. Food and Drug Administration approval, so people with severe allergies don’t have to endure needle-injection of epinephrine, which can ...